• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    2/15/22 4:36:09 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SOPH alert in real time by email
    SC 13G/A 1 g44783922a.htm SCHEDULE 13G


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*



      SOPHiA GENETICS SA
    ______________________________________________
    (Name of Issuer)


    Ordinary Shares
    ______________________________________________
    (Title of Class of Securities)


    H82027105
    ______________________________________________
    (CUSIP Number)



    December 31, 2021
    ______________________________________________
    (Date of Event Which Requires Filing of This Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
       ☐
    Rule 13d1(b)
     
       ☐
    Rule 13d1(c)
     
       ☒
    Rule 13d1(d)
     


    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    1



    1
    NAMES OF REPORTING PERSONS
     
    Generation Investment Management LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY

    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    England and Wales
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,789,560
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,789,560
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    6,789,560
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.6%*
    12
    TYPE OF REPORTING PERSON
     
    IA
    * Beneficial ownership based on 63,857,604 ordinary shares, based on the 63,338,111 ordinary shares expected to be outstanding as of July 27, 2021, as reported on the Issuer’s Prospectus filed pursuant to Rule 424(b)(4) filed with the Securities and Exchange Commission (the “SEC”) on July 23, 2021 plus the 519,493 ordinary shares reported, on the Issuer’s Form 6-K filed on August 25, 2021, as being issued and sold to the underwriters of its initial public offering pursuant to the underwriters’ exercise of their option to purchase additional shares.




    2



    1
    NAMES OF REPORTING PERSONS
     
    Generation IM Sustainable Solutions GP III Limited
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY

    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Guernsey
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,789,560
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,789,560
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    6,789,560
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.6%*
    12
    TYPE OF REPORTING PERSON
     
    OO
    * Beneficial ownership based on 63,857,604 ordinary shares, based on the 63,338,111 ordinary shares expected to be outstanding as of July 27, 2021, as reported on the Issuer’s Prospectus filed pursuant to Rule 424(b)(4) filed with the SEC on July 23, 2021 plus the 519,493 ordinary shares reported, on the Issuer’s Form 6-K filed on August 25, 2021, as being issued and sold to the underwriters of its initial public offering pursuant to the underwriters’ exercise of their option to purchase additional shares.






    3




    1
    NAMES OF REPORTING PERSONS
     
    Generation IM Sustainable Solutions Fund III, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (c) ☐
    (d) ☐
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Guernsey
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,789,560
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,789,560
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    6,789,560
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.6%*
    12
    TYPE OF REPORTING PERSON
     
    OO
    * Beneficial ownership based on 63,857,604 ordinary shares, based on the 63,338,111 ordinary shares expected to be outstanding as of July 27, 2021, as reported on the Issuer’s Prospectus filed pursuant to Rule 424(b)(4) filed with the SEC on July 23, 2021 plus the 519,493 ordinary shares reported, on the Issuer’s Form 6-K filed on August 25, 2021, as being issued and sold to the underwriters of its initial public offering pursuant to the underwriters’ exercise of their option to purchase additional shares.



    4

    Explanatory Note:  This amendment is being filed solely to correct the name of one of the reporting persons. No other changes are being reported by this Amendment.

    Item 1(a)
    Name of Issuer:
     
    SOPHiA GENETICS SA
       
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
       
     
    Rue du Centre 172
     
    CH-1025 Saint-Sulpice
     
    Switzerland
       
       
    Items 2(a)
    Name of Person Filing:
       
     
    Generation Investment Management LLP
     
    Generation IM Sustainable Solutions GP III Limited
     
    Generation IM Sustainable Solutions Fund III, L.P.
       
    Item 2(b)
    Address of Principal Business Office:
       
     
    Generation Investment Management LLP: 20 Air Street, 7th floor, London, United Kingdom W1B 5AN.
     
    Generation IM Sustainable Solutions GP III Limited: 20 Air Street, 7th floor, London, United Kingdom W1B 5AN.
     
    Generation IM Sustainable Solutions Fund III, L.P.: 20 Air Street, 7th floor, London, United Kingdom W1B 5AN.
       
    Item 2(c)
    Citizenship:
       
     
    Generation Investment Management LLP – England and Wales
     
    Generation IM Sustainable Solutions GP III Limited – Guernsey
     
    Generation IM Sustainable Solutions Fund III, L.P. – Guernsey
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Ordinary Shares
       
    Item 2(e)
    CUSIP Number:
       
     
    H82027105
       
       
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:
       
     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Act;
     
    (b)
    ☐
    Bank as defined in Section 3(a)(6) of the Act;
     
    (c)
    ☐
    Insurance company as defined in Section 3(a)(19) of the Act;
     
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act of 1940;
     
    (e)
    ☐
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
     
    (g)
    ☐
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
     
    (j)
    ☐
    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
     
    (k)
    ☐
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
           
    5



    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
       
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       
     
    If this statement is being filed to report the fact that as of the date hereof a reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [  ].
       
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    N/A
       
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
     
    N/A
       
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    N/A
       
       
    Item 9
    Notice of Dissolution of Group:
       
     
    N/A
       
       
    Item 10
    Certification:
       
     
    N/A
       







    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: February 15, 2022
     
     
    GENERATION INVESTMENT MANAGEMENT LLP
           
     
     
     
     
     
     
    By:
     /s/ Alexander Marshall
     
     
    Name:
     Alexander Marshall
     
     
    Title:
    Partner
           
           
     
    GENERATION IM SUSTAINABLE SOLUTIONS GP III LIMITED
     
     
     
     
     
     
    By:
     /s/ Anne Ewing
     
     
    Name:
    Anne Ewing
     
     
    Title:
    Director
           
           
     
    GENERATION IM SUSTAINABLE SOLUTIONS FUND III, L.P.
     
    By: Generation IM Sustainable Solutions GP III Limited
    Its: General Partner
     
     
     
     
     
     
    By:
     /s/ Anne Ewing
     
     
    Name:
    Anne Ewing
     
     
    Title:
    Director
    Get the next $SOPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SOPH

    DatePrice TargetRatingAnalyst
    12/18/2024$11.00Buy
    Craig Hallum
    8/7/2024$10.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$6.00Buy
    Guggenheim
    11/29/2023$8.00Outperform
    RBC Capital Mkts
    7/5/2023$10.00Overweight
    JP Morgan
    1/3/2023$6.00Buy
    BTIG Research
    11/23/2022$2.00Neutral
    Credit Suisse
    2/15/2022$23.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $SOPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on SOPHiA GENETICS SA with a new price target

      Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00

      12/18/24 7:54:16 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS SA downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded SOPHiA GENETICS SA from Overweight to Equal-Weight and set a new price target of $5.00 from $10.00 previously

      8/7/24 11:39:17 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on SOPHiA GENETICS SA with a new price target

      Guggenheim initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00

      6/27/24 7:51:58 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Financials

    Live finance-specific insights

    See more
    • SOPHiA GENETICS Reports First Quarter 2025 Results

      BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

      5/6/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

      BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be

      4/22/25 8:00:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

      BOSTON and ROLLE, Switzerland, March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectivelyOperating loss was $17.4 m

      3/4/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Leadership Updates

    Live Leadership Updates

    See more
    • SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

      BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

      11/5/24 6:32:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

      New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

      5/30/24 12:19:00 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

      Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology

      5/31/23 9:12:00 AM ET
      $SOPH
      $XYL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Fluid Controls
      Industrials

    $SOPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SOPHiA GENETICS Reports First Quarter 2025 Results

      BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

      5/6/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

      BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (NASDAQ:AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025. Developed in collaboration with Memorial Sloan Kettering Cancer Cen

      4/28/25 12:00:00 PM ET
      $AZN
      $SOPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

      BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be

      4/22/25 8:00:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    SEC Filings

    See more
    • SEC Form 144 filed by SOPHiA GENETICS SA

      144 - SOPHiA GENETICS SA (0001840706) (Subject)

      5/19/25 4:21:14 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by SOPHiA GENETICS SA

      6-K - SOPHiA GENETICS SA (0001840706) (Filer)

      5/16/25 9:53:25 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by SOPHiA GENETICS SA

      6-K - SOPHiA GENETICS SA (0001840706) (Filer)

      5/8/25 2:23:03 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SOPHiA GENETICS SA

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      11/13/24 3:31:21 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      2/20/24 4:55:59 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      2/14/24 11:23:25 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care